Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT06706401 2026-04-24

LYSARI

Phase 3 Recruiting

460 enrolled

Head & Neck

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT06536413 2026-04-03

ATRA

Phase 1/2 Recruiting

42 enrolled

Plasma cell

Multiple Myeloma

NCT05345002 2026-02-20

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Phase 2 Recruiting

55 enrolled

CNS

Astrocytoma, Glioma, Oligodendroglioma

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06358677 2026-02-13

FACE

Phase 2 Recruiting

25 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

10 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

170 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04113863 2025-12-18

ATRA

Phase 2 Terminated

76 enrolled

Breast

Breast Neoplasm Female

NCT06439888 2025-12-01

LySATRA

Phase 1/2 Recruiting

58 enrolled

Other solid neoplasm

Oligometastatic Disease

NCT06731140 2025-11-17

Resilire

Phase 2 Recruiting

10 enrolled

Breast

HER2 Negative Breast Cancer

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Phase 2 Recruiting

16 enrolled

Sarcoma

Leiomyosarcoma, Sarcoma

NCT07187505 2025-09-23

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Phase NA Active not recruiting

28 enrolled

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT05999812 2025-05-25

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Phase 2 Active not recruiting

22 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04700176 2025-02-25

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Phase 2 Terminated

1 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT06728631 2025-02-24

Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Phase 2 Active not recruiting

22 enrolled

Head & Neck

Mouth Neoplasms

NCT06158412 2025-02-19

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Phase 2 Recruiting

25 enrolled

Plasma cell

Multiple Myeloma

NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Phase 2 Not yet recruiting

35 enrolled

Lymphoid

Lymphoma, B-Cell

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Phase 1/2 Completed

26 enrolled 13 charts

Dermatologic

Melanoma

NCT05482451 2024-08-21

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Phase EARLY_PHASE1 Active not recruiting

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05832320 2024-05-10

Optimum Induction Therapy of Low-risk APL

Phase NA Unknown

74 enrolled

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT02942758 2024-05-08

AML-ViVA

Phase 2 Terminated

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03572387 2024-04-30

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Phase 2 Completed

14 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04793919 2024-04-15

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Phase 2 Recruiting

89 enrolled

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02403778 2023-09-21